These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 7911844

  • 21. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.
    Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, Gazdar AF.
    J Natl Cancer Inst; 1993 Jun 02; 85(11):897-901. PubMed ID: 8098377
    [Abstract] [Full Text] [Related]

  • 22. HER2/neu immunostaining in pancreatic carcinoma.
    Battifora H.
    Hum Pathol; 1994 May 02; 25(5):549-50. PubMed ID: 7911120
    [No Abstract] [Full Text] [Related]

  • 23. Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
    Wakelee HA.
    Clin Adv Hematol Oncol; 2014 Jan 02; 12(1 Suppl 1):17-21. PubMed ID: 24852399
    [No Abstract] [Full Text] [Related]

  • 24. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.
    David O, LeBeau H, Brody AR, Friedman M, Jett J.
    Chest; 2004 May 02; 125(5 Suppl):152S. PubMed ID: 15136478
    [No Abstract] [Full Text] [Related]

  • 25. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
    Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG.
    J Thorac Cardiovasc Surg; 1994 Feb 02; 107(2):590-5. PubMed ID: 7905543
    [Abstract] [Full Text] [Related]

  • 26. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast.
    Maguire HC, Greene MI.
    Pathobiology; 1990 Feb 02; 58(6):297-303. PubMed ID: 1981830
    [Abstract] [Full Text] [Related]

  • 27. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS.
    J Clin Oncol; 2015 Aug 01; 33(22):2472-80. PubMed ID: 26124487
    [Abstract] [Full Text] [Related]

  • 28. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S.
    Ann Pathol; 2016 Jan 01; 36(1):94-102. PubMed ID: 26778219
    [Abstract] [Full Text] [Related]

  • 29. Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer.
    Stahel RA.
    Lung Cancer; 1994 Nov 01; 11 Suppl 3():S31-8. PubMed ID: 7704510
    [No Abstract] [Full Text] [Related]

  • 30. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
    Ikeda N, Nagase S, Ohira T.
    Ann Thorac Cardiovasc Surg; 2009 Jun 01; 15(3):144-9. PubMed ID: 19597387
    [Abstract] [Full Text] [Related]

  • 31. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1536-48. PubMed ID: 15494604
    [Abstract] [Full Text] [Related]

  • 32. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
    Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH.
    Clin Cancer Res; 2000 Dec 20; 6(12):4932-8. PubMed ID: 11156254
    [Abstract] [Full Text] [Related]

  • 33. ALK testing in non-small cell lung carcinoma: what now?
    Kerr KM.
    J Thorac Oncol; 2014 May 20; 9(5):593-5. PubMed ID: 24722149
    [No Abstract] [Full Text] [Related]

  • 34. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T.
    J Thorac Oncol; 2010 Sep 20; 5(9):1317-24. PubMed ID: 20736805
    [Abstract] [Full Text] [Related]

  • 35. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
    Zhao H, Xie YZ, Xing R, Sun M, Chi F, Zeng YC.
    Cell Oncol (Dordr); 2017 Aug 20; 40(4):357-365. PubMed ID: 28567715
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Outcome of crizotinib treatment in a young woman with heavily pretreated ROS1-positive lung cancer.
    Petreni P, Mazzoni F, Meoni G, Lunghi A, Cecere FL, Muto A, Di Costanzo F.
    Tumori; 2015 Jun 25; 101(3):e103-6. PubMed ID: 25908037
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE, Abdelrahman AE, Abdelgawad M, Balata S, Shabrawy ME.
    Turk Patoloji Derg; 2017 Jun 25; 1(1):211-222. PubMed ID: 28832075
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.